Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.39 |
| ▸ | ITGAV | P06756 | 6/20 | 0.39 |
| ▸ | NAMPT | P43490 | 5/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029576 | 0.93 | ITGB3 (0.44) | ITGB3ITGAVNAMPTITGA2BCTSS | |
| SCHEMBL7034232 | 0.92 | ITGB3 (0.40) | ITGB3ITGAVNAMPTITGA2BLMNA | |
| SCHEMBL7036608 | 0.91 | ITGB3 (0.43) | ITGB3ITGAVNAMPTITGA2BCTSL | |
| SCHEMBL7038294 | 0.91 | NAMPT (0.41) | ITGB3ITGAVNAMPTITGA2BLMNA | |
| SCHEMBL7030829 | 0.91 | NAMPT (0.51) | ITGB3ITGAVNAMPTITGA2BLMNA | |
| SCHEMBL7033860 | 0.91 | ITGB3 (0.48) | ITGB3ITGAVNAMPTITGA2BCTSL | |
| SCHEMBL7037009 | 0.91 | NAMPT (0.40) | ITGB3ITGAVNAMPTITGA2BCTSK | |
| SCHEMBL7035656 | 0.90 | NAMPT (0.38) | ITGB3ITGAVNAMPTITGA2BCTSL | |
| SCHEMBL7032579 | 0.90 | ITGB3 (0.49) | ITGB3ITGAVNAMPTITGA2BCTSL | |
| SCHEMBL7393007 | 0.89 | ITGB3 (0.47) | ITGB3ITGAVNAMPTITGA2BCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | claimed |
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
| WO-1999052879-A1 | ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | ITGB3 403/4885ITGAV 289/4885NAMPT 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.